" "The recommendation was based solely on orphan market exclusivity and not the safety and efficacy profile of taliglucerase alfa," said Diem Nguyen, General Manager for Biosimilars, Pfizer. "Pfizer will continue to work with relevant stakeholders to determine appropriate next steps."
Well, no doubt they will. What is amazing is that the respective managements of Protalix and Pfizer, when speaking about Europe throughout the last year, have not done a better job explaining the risks to the shareholders. Most investors have been believing that the EMA approval would be certain and that after the FDA approval, we were only facing some kind of technical delay. After the first NDA fiasco, Protalix management should have acted differently - but it is what it is. "
totally agree! I don't like the management praoctices in this matter and I hope a class action will not be filled soon...
this is not the first time i feel the dosclosure is improper but I still give mamagememt the benefit of the doubt. this also include the fact they sold shares immediately after FDA approval assuming, i believe, that the strong momentum will stop... and they were right.
But I am still holding the stock hoping that indeed we have here a new platform and not a one time case of a new drug with very limited market...
we know it is all taking time but still I feel bad about the management disclosure.
It is so ironic that I sold all my PLX stock way back on the day of the FDA rejection in March of 2011 at $6.85 a share, and now with approval it is down to $5.73. I feel for you guys. Hopefully, Pfizer will be able to use its influence to get into the European market.